CNCR
Range Cancer Therapeutics ETF
This fund tracks the Loncar Cancer Immunotherapy Index, an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.
US
EQUITY
Passive
MANAGEMENT STYLE
10.0 M
ASSETS UNDER MGMT
79 bp
EXPENSES
Fund Basics
| Fund sponsor | US Bancorp |
| Category | US |
| Asset class | Equity |
| Website | link... |
| Inception date | Oct 13, 2015 |
| Assets (mns) | $10 |
| Expense ratio | 79 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-End Investment Company |
| Distributions | Annually |
| Taxation | 1099 |
| Stock selection | Market Cap |
| Weighting | Equal |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| RECURSION PHARMACEUTICALS, INC CLASS A | 3.3 % |
| GINKGO BIOWORKS HOLDINGS INC CLASS A | 2.4 % |
| INNATE PHARMA SA | 2.2 % |
| MONTE ROSA THERAPEUTICS, INC. | 2.1 % |
| EXELIXIS INC | 2.0 % |
| JANUX THERAPEUTICS, INC. | 1.9 % |
| REPLIMUNE GROUP, INC. | 1.9 % |
| XENCOR INC | 1.8 % |
| BRISTOL-MYERS SQUIBB CO | 1.8 % |
| MERSANA THERAPEUTICS, INC. | 1.7 % |
Constituent Breakdown
| Number of holdings | 72 |
| Herfindahl-Hirschman Index | 143 |
| Wgt avg mkt cap (mns) | $8,411 |
| Large cap (>$10bn) | 10.5% |
| Mid cap ($2-10bn) | 13.9% |
| Small cap (<$2bn) | 75.6% |
| Developed mkts. | 100.0% |
| Emerging mkts. | 0.0% |
Country Exposure
 |
UNITED STATES | 82.5 % |
 |
CANADA | 2.4 % |
 |
GERMANY | 2.4 % |
 |
BRITAIN | 2.4 % |
 |
HONG KONG | 1.5 % |
 |
NETHERLANDS | 1.4 % |
 |
DENMARK | 1.2 % |
Historical Performance
Standardized Performance (as of 11/30/2024)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | Incep. | |
|---|---|---|---|---|---|---|---|
| Total Returns | 10.7% | 35.4% | 0.0% | -15.7% | -7.1% | -- | -5.5% | Volatility | 35.1% | 36.0% | 32.3% | 35.6% | 35.5% | -- | -- |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.93 | 25% |
| MSCI EAFE | 0.87 | 21% |
| MSCI Emg Mkts | 0.63 | 11% |
Liquidity Measures
| Avg. volume (000) | 3 |
| Turnover | 0.4% |
| Avg. Bid/Ask (% of price) | 1.00% |
| ADV of underlying (mns) | $2,817 |
Technical Indicators
| Recent close | $12.02 |
| 30d moving avg. | $13.70 |
| Annualized volatility | 32.7% |
| Relative strength (RSI) | 48 |
| Short interest (ETF) | 0.2% |
| Short interest (underlying) | 4.9% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. CNCR |
Expenses vs. CNCR |
ALTAR Score™ vs. CNCR |
|---|---|---|---|---|
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 25.6% | 0 bp | 0.0% |
| CANC | Tema Oncology ETF | 25.0% | -4 bp | -3.9% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 18.4% | -32 bp | -4.4% |
| BBP | Virtus LifeSci Biotech Products ETF | 15.9% | 0 bp | 0.0% |
| SBIO | ALPS Medical Breakthroughs ETF | 14.4% | -29 bp | -1.9% |
| XBI | SPDR S&P BIOTECH ETF | 14.3% | -44 bp | -3.3% |
| WDNA | WisdomTree BioRevolution Fund | 13.0% | -34 bp | -3.9% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 11.3% | -60 bp | +0.9% |
| IBB | iShares Biotechnology ETF | 10.6% | -34 bp | +0.3% |
Risk and Returns: CNCR vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
EPS Revision Activity (6 mo. ago = 100%)
Compound Annual Growth Rates
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| 2023 | 2024E | Fwd Est | 2025E | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 12/18/2024
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
CNCR
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
AVOID
Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may be less relevant.
ALTAR Score™
CNCR
0.0%
Cat. Avg
5.7%
ALTAR Score™ Calculation
Category Overview
There are 977 funds in the US Equity category, with an average ALTAR Score™
of 5.7% and a standard deviation of
2.6%. CNCR's ALTAR Score™ is approximately
2.2 standard deviations
below
the category average. This places CNCR in the 1st percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
CNCRSELL
U/W
HOLD
O/W
BUY
Expense Analysis
| Peer Group | Passive US Equity ETFs |
| # of ETFs | 192 |
| Avg. Expense Ratio | 31.0 bp |
| Std. Deviation | 25.7 bp |
| CNCR (79 bp) Percentile rank | 97 |
Peer Group Expense Ratio Distribution
Total Cost of Ownership (TCO) Comparison
| Expense (bp) (A) |
Avg. Bid/Ask (bp) (B) |
TCO (bp) (A)+(B) |
|
|---|---|---|---|
| CNCR | 79.0 | 100.0 | 179 |
| Peer Avg. | 26.7 | 10.6 | 37.3 |
For a detailed cost analysis of this and any other ETF use the TCO Comparison Tool .